Loading
A phase 1/2 trial of ZG006 in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.
Study of ZGGS34 in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07258121 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 400 participants planned, started 2025-12-31 and due to reach its primary completion in 2028-12. Interventions recorded: ZG006.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares Suzhou Zelgen Biopharmaceuticals and the tag pipeline.
Shares ZG006, Suzhou Zelgen Biopharmaceuticals.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/